LC350189 + colchicine

LC350189 + colchicine is a combination drug consisting of LC350189 (known as tigulixostat) and colchicine. LC350189 is a novel, non-purine, selective xanthine oxidase inhibitor developed for the management of hyperuricemia and gout; it operates by inhibiting xanthine oxidase, which reduces uric acid production[2][3][4]. Colchicine is a microtubule inhibitor used for the treatment and prevention of gout flares, acting primarily by blocking neutrophil inflammation and migration[1][5]. This combination may be considered for the management and prophylaxis of gout, targeting both uric acid reduction and the acute inflammatory response.

Brand names

Tigulixostat

Other names

LC350189LC-350189LC 350189tigulixostatcolchicine